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Summary
Snake envenoming is uncommon but potentially 
life-threatening. It is characterised by systemic 
effects including coagulopathy, neurotoxicity, 
myotoxicity and renal impairment. Pressure 
immobilisation bandaging is safe and appears to be 
effective first aid if applied correctly soon after the 
bite. Each Australian snake causes a characteristic 
clinical syndrome which can be used with 
information about the geographical distribution of 
snakes to determine which snake is involved when 
a patient is envenomed. Snake venom detection 
kits are available to help identify the causative 
snake. Antivenoms are available for the five major 
groups of snakes and are the mainstay of therapy 
in patients with systemic envenoming. Antivenom 
should be administered by slow intravenous 
infusion in a critical care area. Serious adverse 
reactions to antivenoms are uncommon.
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Introduction
Australia has a unique snake fauna including snakes with 
highly potent venoms. The major Australian snakes are the 
brown snakes, tiger snake group, mulga/black snakes, taipans 
and death adders. Estimates suggest that there are between 
500 and 3000 snake bites annually. In about 200 to 500 cases 
antivenom is required.1,2 Snake envenoming is an uncommon 
but potentially life-threatening medical condition.3 Between 
one and four deaths occur each year with most resulting from 
brown snake bites. Bites occur in the warmer months and are 
more common in regional and rural areas. Exotic snakes are 
kept legally in zoos and illegally by collectors so bites by non-
Australian snakes sometimes occur.
Clinical effects
In many snake bites only local effects occur because 
insufficient venom is injected or the snake is non-venomous. 
With more significant envenoming there may be local or 
systemic effects. These range from non-specific effects (nausea, 
vomiting, headache, abdominal pain, diarrhoea, dizziness and 
collapse) to major organ effects (coagulopathy, neurotoxicity, 
rhabdomyolysis or renal damage).4
Local effects
Brown snake bites have minimal local effects, whereas local 
pain, swelling and occasionally tissue injury can follow black 
and tiger snake bites. Bites from some snakes such as whip 
snakes (Demansia species) can cause immediate significant 
local swelling and pain.
Coagulopathy
The majority of dangerous Australian snakes cause a 
procoagulant coagulopathy. The venom contains a prothrombin 
activator that leads to consumption of major coagulation factors 
including fibrinogen, resulting in a defibrination coagulopathy 
which should be referred to as venom-induced consumptive 
coagulopathy. This is characterised by very high d-dimers, 
undetectable fibrinogen, and unrecordable prothrombin time 
and activated partial thromboplastin time. Recovering from this 
takes many hours after venom neutralisation has been achieved 
with antivenom.
Some black snakes (mulga and Collett's snake) cause an 
anticoagulant coagulopathy, probably due to an inhibitor, that 
is rapidly reversed with antivenom. It is not associated with 
consumption of clotting factors, so fibrinogen and d-dimer 
levels are normal.
Neurotoxicity
Paralysis is a classic effect of snake bite and is due to 
presynaptic or postsynaptic neurotoxins in the venom. 
Presynaptic neurotoxins disrupt neurotransmitter release from 
the terminal axon. This takes days to resolve and does not 
respond to antivenom. Postsynaptic neurotoxins competitively 
block acetylcholine receptors but the effect can be reversed by 
antivenom.
Neurotoxic envenoming causes a progressive descending 
flaccid paralysis. Ptosis is usually the first sign, then facial and 
bulbar involvement progressing to paralysis of the respiratory 
muscles and peripheral weakness in severe cases.
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Myotoxicity
Some Australian snakes, such as the mulga snakes and 
tiger snakes, have venom containing myotoxins that cause 
rhabdomyolysis with muscle pain, tenderness and weakness, a 
rapidly rising creatine kinase and myoglobinuria.
Renal damage
Renal impairment or acute renal failure can occur secondary to 
severe rhabdomyolysis, in association with microangiopathic 
haemolytic anaemia (reported with brown snakes) or can occur 
rarely in isolation.
Major types of Australian snakes: clinical 
syndromes
The five major groups of medically important Australian snakes 
which cause characteristic clinical syndromes are included in 
Table 1. Identifying the snake is important for diagnosis and 
determining the appropriate antivenom to be administered, but 
is not always possible. Venom detection kits are available to 
assist with identification.
Brown snakes
Brown snakes occur widely throughout mainland Australia. They 
are fast moving and easily alarmed snakes that strike readily. 
However, they have a high rate of dry bites with envenoming 
occurring in less than half of bites. Bites cause minimal local 
effects and non-specific systemic effects are uncommon. Severe 
envenoming is characterised by an early collapse, within an 
hour of the bite, usually with spontaneous recovery within 5 to 
10 minutes. Collapse appears to occur at the time of onset of the 
coagulopathy, but the mechanism is unclear. The major clinical 
feature is a venom-induced consumption coagulopathy.4 Renal 
damage and microangiopathic haemolytic anaemia have been 
reported and neurotoxicity is rare.
Tiger snake groups
Tiger snakes occur in southern and eastern Australia. The major 
clinical effects are a venom-induced consumption coagulopathy, 
presynaptic neurotoxicity and rhabdomyolysis. An early collapse 
can occur and initially the only detectable effect may be a 
coagulopathy.
Rough-scaled snakes are closely related to tiger snakes and 
cause similar effects. Copperheads are less well characterised, 
but appear to cause neurotoxicity and coagulopathy. The 
Hoplocephalus genus (Table 1) cause coagulopathy and are 
clinically similar to brown snakes except that tiger snake 
antivenom is used for treatment.
Mulga and black snake groups
Mulga snakes occur across Australia except the south and 
east. They cause severe rhabdomyolysis and anticoagulant 
coagulopathy associated with non-specific symptoms. Collett's 
snake causes a similar clinical picture, but only bites in snake 
handlers have been reported due to its isolated distribution. 
The red-bellied black snake is common in southern and eastern 
Australia, but only causes non-specific systemic effects, mild 
rhabdomyolysis and local effects which are usually managed 
without antivenom. 
Taipans
Taipans occur in northern Australia and are very dangerous 
with a high envenoming rate. The mortality rate is high in 
untreated cases. Clinical effects include a venom-induced 
consumption coagulopathy, presynaptic neurotoxicity and mild 
rhabdomyolysis. Thrombotic microangiopathy, haemolytic 
anaemia and renal failure have been rarely reported.
Death adders
Death adders are widespread but secretive ambush predators 
that have a characteristic 'viper-like' appearance. The major 
clinical effect is a postsynaptic neurotoxicity associated with 
non-specific systemic features.4
Diagnosis
In the majority of cases there is a history of a snake bite or 
suspected snake bite. History, examination and investigations 
focus on whether the patient is envenomed or not and by which 
snake so that the correct antivenom can be given. Occasionally 
the diagnosis is not obvious if a snake is not seen or the patient 
presents with coagulopathy or neurotoxicity and no history of  
a bite.
A careful history is required to determine the circumstances of 
the bite and what first aid has been applied. Early symptoms 
suggest severe envenoming. The examination should include 
the bite site, and palpation of the lymph nodes draining the 
site for tenderness. In addition to standard observations, the 
examination includes looking for signs of paralysis (ptosis, 
bulbar palsy, respiratory effort and peripheral weakness), 
any evidence of coagulopathy (bleeding) or evidence of 
rhabdomyolysis (muscle tenderness and weakness). 
Investigations should include a full blood count, coagulation 
studies including d-dimer, and biochemical tests including 
creatine kinase. A urine analysis is helpful for detecting blood or 
myoglobin. 
A whole blood clotting time may be useful if coagulation 
studies are not available. Blood is collected in a clean glass 
tube and the time to clot is measured. The normal clotting 
time is less than 10 minutes. If the clotting time is greater 
than 20 minutes, this is highly suggestive of a procoagulant 
coagulopathy. If the clotting time is between 10 and 20 
minutes, the result is indeterminate, but may be consistent 
with an anticoagulant coagulopathy.5 This test may be useful 
in remote situations to determine if a patient has significant 
coagulopathy. 
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Significant systemic envenoming has been defined as any of the 
following:
■ neurotoxic paralysis
■ coagulopathy (confirmed by laboratory)
■ myotoxicity
■ renal impairment/failure.
Determination of the snake involved and more importantly the 
selection of the appropriate monovalent antivenom is based on:
■ knowledge of the local snake fauna
■ clinical syndrome
■ snake venom detection kit.
Snake venom detection kit
The snake venom detection kit is a useful diagnostic test to 
confirm which of the five major snake groups is responsible 
for the envenoming. This will determine which antivenom is 
needed. The test is therefore only useful in healthcare facilities 
that have antivenom supplies. It should be done in a laboratory. 
The test has no value in non-envenomed patients because of 
false positives and it cannot be used to confirm or exclude 
snake envenoming. In many cases the determination of the 
snake involved can be made on geographical and clinical 
grounds, and results from the venom detection kit should 
always be interpreted in the context of these. It is prudent to 
collect and store bite site swabs for venom detection in all 
suspected snake bite cases and only do the test in cases where 
envenoming is confirmed and antivenom is required.
Management of snake bite
Many snake bites do not result in envenoming. The rate of 
envenoming varies depending on the species of snake. Whether 
envenoming has occurred cannot be immediately determined 
when the patient presents. This means all suspected snake bites 
must be triaged as a medical emergency and observed for a 
sufficient period of time in a hospital with adequate supplies of 
antivenom and laboratory facilities. Immediate expert advice 
can be obtained from the Poisons Information Centre network 
(phone 13 11 26).
First aid
The bite site should not be washed so that the area can be 
swabbed for venom detection. Pressure immobilisation is the 
recommended first aid treatment for all snake bites.6 It has been 
effective in animal studies and case studies, but has not been 
tested in clinical trials. 
A broad (15 cm) bandage is applied at the same pressure as 
for a sprained ankle over the entire limb. The patient must 
then remain completely immobilised, not just the bitten limb. 
For bites on areas other than limbs the patient should be 
immobilised to slow the spread of venom.
Pressure immobilisation should only be removed once the 
patient is in a hospital stocked with antivenom. If the patient 
is envenomed, pressure immobilisation can be removed once 
antivenom therapy has commenced. If the patient has no 
clinical or laboratory signs of envenoming, the bandage can 
be removed if antivenom and resuscitation equipment are 
available. 
General management
Initial management includes basic resuscitation and assessment 
of the patient. Once airway, breathing and circulation have been 
assessed and stabilised, the diagnosis can be made and specific 
management undertaken. 
All cases of suspected snake bite should be observed for 
sufficient time to exclude delayed envenoming. Close 
observation is needed to look for early signs of neurotoxicity 
such as ptosis.3 There has been significant controversy over 
the appropriate duration of observation and this is highly 
dependent on regional snake fauna and healthcare facilities. The 
current recommendation is that patients should be observed 
for a period of at least 12 hours and if this period extends into 
the night the patient should remain overnight. The duration 
of observation may be longer in regions where delayed 
envenoming occurs, for example the delayed neurotoxicity 
following death adder bites in northern Australia.4 
The patient is unlikely to be envenomed if they have normal 
laboratory tests on admission, 1–2 hours after pressure 
immobilisation removal and before discharge.
Wound site infection is rare and only requires treatment if there 
is clear clinical evidence of an infection. Local swelling often 
resolves without treatment so antibiotics are not recommended. 
Tetanus prophylaxis is recommended for all bites.
Antivenom
Antivenom is the mainstay of treatment in patients with 
systemic envenoming (see Table 2). It is not recommended in 
patients who only manifest non-specific features as these may 
be misleading. Antivenom should always be administered 
intravenously after 1:10 dilution with normal saline or 
Hartmann's solution. The degree of dilution may need to be 
modified for large volume antivenoms and in young children. 
Premedication with adrenaline, antihistamines or corticosteroids 
is not recommended, but the patient must be monitored in a 
critical care area with adrenaline and resuscitation equipment 
readily available.
After the first dose, further doses and the intervals between 
them are dependent on the type of snake, the reversibility of the 
clinical effects and the time it takes the body to recover once the 
venom has been neutralised. The response to antivenom differs 
for the various clinical and laboratory effects. The postsynaptic 
neurotoxicity seen with death adder bites is reversed by 
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antivenom, but presynaptic neurotoxicity seen with taipan and 
tiger snakes is irreversible once it has developed and antivenom 
will only prevent further progression. Procoagulant toxins are 
neutralised by antivenom, but recovery of normal coagulation 
takes 6–12 hours on average. Anticoagulant coagulopathy is 
rapidly reversed by antivenom. Development or progression of 
rhabdomyolysis can be prevented by antivenom but it cannot 
be reversed.
There continues to be debate about initial doses, further doses 
and the dosing interval7 and discussion with an expert is 
often safest. The Australian Snakebite Project is a multicentre 
prospective study of snake bite where serial samples are 
being collected for quantification of venom and antivenom 
concentrations. This study should help to address the questions 
of initial dose and appropriate laboratory and clinical end points 
for antivenom treatment. (Patients can be enrolled by contacting 
the Poisons Information Centre or the author).
Adverse effects
Early and delayed allergic reactions can occur with any 
antivenom, but are uncommon with Australian antivenoms. 
Early allergic reactions occur in less than 5% of cases 
and are thought to be due to complement activation. True 
hypersensitivity reactions are rare except in snake handlers who 
have had previous exposure to antivenom.
Serum sickness is a delayed reaction that develops 5–10 days 
after antivenom administration and is characterised by fever, 
rash, arthralgia, myalgia and non-specific systemic features. This 
should be treated with a one-week course of corticosteroids. 
When greater than 25 mL of antivenom is administered it is 
advisable to give a prophylactic course of oral corticosteroids. 
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Table 2
Potential benefits of antivenom
Clinical effect Benefits
Procoagulant coagulopathy Neutralises toxin effect allowing clotting factors to be resynthesised and clotting to  
    recover over 6–12 hours
Anticoagulant coagulopathy Neutralises a toxin inhibitor of coagulation with immediate improvement in  
    coagulation studies
Presynaptic neurotoxicity Neutralises toxin in the intravascular compartment and will prevent further  
    development of neurotoxicity but not reverse already present neurotoxic effects
Postsynaptic neurotoxicity Neutralises toxin in the intravascular compartment and reverses neurotoxicity
Rhabdomyolysis Neutralises myotoxins and will prevent further muscle injury but not reverse  
    myotoxic effects
Local effects Unlikely to reverse any local effects that have already developed
Renal damage Unlikely to have any discernible effect because this is usually secondary to other  
    toxin-mediated effects
Generalised systemic effects: nausea,  Rapidly reverse non-specific effects. This is a useful indication of antivenom efficacy 
   vomiting, headache, abdominal pain,  
   diarrhoea and diaphoresis 
